Next Article in Journal
Antioxidant Activity of Myrtus communis L. and Myrtus nivellei Batt. & Trab. Extracts: A Brief Review
Next Article in Special Issue
Schizophrenia and Sleep Disorders: An Introduction
Previous Article in Journal
Anticancer Effects of Green Tea and the Underlying Molecular Mechanisms in Bladder Cancer
Previous Article in Special Issue
Pharmacological Treatment for Long-Term Patients with Schizophrenia and Its Effects on Sleep in Daily Clinical Practice: A Pilot Study
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessFeature PaperReview
Medicines 2018, 5(3), 88; https://doi.org/10.3390/medicines5030088

Pharmacologic Treatment Options for Insomnia in Patients with Schizophrenia

1
McLean Hospital, Belmont, MA 02478, USA
2
Hackensack University Medical Center-Hackensack Meridian Health, Hackensack, NJ 07601, USA
3
Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey, Piscataway, NJ 08854, USA
4
Monmouth Medical Center-RWJBarnabas Health, Long Branch, NJ 07740, USA
*
Author to whom correspondence should be addressed.
Received: 29 June 2018 / Revised: 8 August 2018 / Accepted: 10 August 2018 / Published: 11 August 2018
(This article belongs to the Special Issue Schizophrenia and Sleep Disorders)
Full-Text   |   PDF [280 KB, uploaded 14 August 2018]

Abstract

Background: Symptoms of sleep disorders, such as disturbances in sleep initiation and continuity, are commonly reported in patients with schizophrenia, especially in the acute phase of illness. Studies have shown that up to 80% of patients diagnosed with schizophrenia report symptoms of insomnia. Sleep disturbances have been shown to increase the risk of cognitive dysfunction and relapse in patients with schizophrenia. Currently, there are no medications approved specifically for the treatment of insomnia in patients with schizophrenia. Methods: A literature search was performed through OVID and PubMed to compile publications of pharmacotherapy options studied to treat insomnia in patients with schizophrenia. Articles were reviewed from 1 January 2000 through 1 March 2018 with some additional earlier articles selected if deemed by the authors to be particularly relevant. Results: Pharmacotherapies collected from the search results that were reviewed and evaluated included melatonin, eszopiclone, sodium oxybate, and antipsychotics. Conclusions: Overall, this review confirmed that there are a few evidence-based options to treat insomnia in patients with schizophrenia, including selecting a more sedating second-generation antipsychotic such as paliperidone, or adding melatonin or eszopiclone. Further randomized controlled trials are needed. View Full-Text
Keywords: insomnia; schizophrenia; pharmacotherapy; paliperidone; melatonin; sodium oxybate; eszopiclone; antipsychotics insomnia; schizophrenia; pharmacotherapy; paliperidone; melatonin; sodium oxybate; eszopiclone; antipsychotics
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Stummer, L.; Markovic, M.; Maroney, M.E. Pharmacologic Treatment Options for Insomnia in Patients with Schizophrenia. Medicines 2018, 5, 88.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Medicines EISSN 2305-6320 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top